IDiyas

For the Inventor, By the Inventor

Osaka, Japan

Hisao Tajima

USPTO Granted Patents = 17

Average Co-Inventor Count = 2.7

ph-index = 5

Forward Citations = 76(Granted Patents)


Location History:

  • Osaka, JP (1996 - 2007)
  • Mishima-gun, JP (2005 - 2009)

Company Filing History:

goldMedal17 out of 574 
 
Ono Pharmaceutical Co., Ltd.
 patents

Years Active: 1996-2009

Loading Chart...
17 patents (USPTO):Explore Patents
1. 7608411 - Prostaglandin receptor EP1 (2009-10-27),
2. 7560475 - Phenylacetic acid derivative, process for producing the same, and use (2009-07-14),
3. 7323456 - Carboxylic acid derivatives compounds and agents comprising the compounds as active ingredient (2008-01-29),
4. 7241784 - Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient (2007-07-10),
5. 7220864 - Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient (2007-05-22),
6. 7211591 - Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient (2007-05-01),
7. 7037914 - Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient (2006-05-02),
8. 6924295 - Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient (2005-08-02),
9. 6855543 - Plasmid DNA containing reporter gene DNA and use of the same (2005-02-15),
10. 6821994 - Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient (2004-11-23),
11. 6664281 - Carboxylic acid derivatives and drugs containing the same as the active ingredient (2003-12-16),
12. 6589969 - Carboxylic acid derivatives and drugs containing the same as the active ingredient (2003-07-08),
13. 6506757 - Carboxylic acid derivatives and drugs containing the same as the active ingredient (2003-01-14),
14. 6432913 - Polypeptide of protein p140 and DNAs encoding it (2002-08-13),
15. 6303320 - Polypeptide of protein P140 and DNAs encoding it (2001-10-16),

Title: Hisao Tajima: Innovator in Pharmaceutical Science

Introduction

Hisao Tajima is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceutical science, particularly in the development of novel compounds and therapeutic agents. With a total of 17 patents to his name, Tajima's work has had a profound impact on medical research and treatment options.

Latest Patents

His latest patents include groundbreaking innovations such as the Prostaglandin receptor EP1. This invention encompasses a novel polypeptide prostaglandin E receptor, a cDNA encoding the polypeptide, and a replication or expression vector carrying the DNA. Additionally, it involves a host cell transformed with the vector, methods for producing the polypeptide, and monoclonal or polyclonal antibodies against the polypeptide. The pharmaceutical composition derived from this invention is designed to treat diseases caused by the overproduction of PGE, including pain, fever, and pollakiuria. Another significant patent involves a phenylacetic acid derivative, which is characterized by low toxicity and is safe for use as a pharmaceutical agent. This compound has PPAR δ agonistic activity, making it useful for treating glucose-lipid metabolic disorders, hypertension, and circulatory diseases.

Career Highlights

Hisao Tajima is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His work has been instrumental in advancing therapeutic options and improving patient outcomes.

Collaborations

Tajima has collaborated with notable colleagues such as Yoshisuke Nakayama and Daikichi Fukushima. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Hisao Tajima's contributions to pharmaceutical science through his numerous patents highlight his role as a leading inventor in the field. His innovative work continues to pave the way for new treatments and advancements in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…